Lansoprazole/β-Cyclodextrin-Based Metal-Organic Frameworks: Development, Characterization, and Anti-Ulcer Activity...

Gastric ulcers are among the most common diseases worldwide, affecting individuals of all ages and genders. Lansoprazole (LNS) is one of the first-choice treatments for ulcers. In this study, β-Cyclodextrin-based metal-organic frameworks (β-CD-MOFs), which have recently attracted attention for biomedical applications, were used as carriers for LNS to enhance its physicochemical properties.

β-CD-MOF crystals were prepared, and LNS was successfully loaded into the crystals in the presence of MgO. Pure LNS and the formulation were characterized using Differential Scanning Calorimetry (DSC), Powder X-Ray Diffraction (PXRD), Fourier-Transform Infrared spectroscopy (FTIR), Scanning Electron Microscopy (SEM), and in vitro release studies. The anti-ulcer activity was evaluated in male Wistar albino rats.

Dissolution studies revealed that approximately 90% of LNS was released from the formulation within 60 minutes, and the formulation's color remained unchanged after exposure to light. The formulation demonstrated a significant reduction in mucosal erythema and mucosal surface lesions, as well as a higher percentage of ulcer index inhibition.

Loading of LNS into β-CD-MOF enhanced its release and photostability. In vivo studies suggest that the formulation has a potent anti-ulcerogenic capability comparable to that of LNS.

β-CD-MOF, a promising carrier in drug delivery, improves the properties of LNS and further enhances its anti-ulcer activity.